BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1138 related articles for article (PubMed ID: 28108967)

  • 21. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
    Ameli F; Rose IM; Masir N
    Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
    World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
    Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
    Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.
    Fortunato L; Mascaro A; Poccia I; Andrich R; Amini M; Costarelli L; Cortese G; Farina M; Vitelli C
    Ann Surg Oncol; 2012 Apr; 19(4):1107-14. PubMed ID: 21913022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
    Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
    BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival.
    Winn JS; Baker MG; Fanous IS; Slack-Davis JK; Atkins KA; Dillon PM
    Oncology; 2016; 91(3):135-42. PubMed ID: 27355204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
    Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
    Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Infiltration in Invasive Lobular Breast Cancer.
    Desmedt C; Salgado R; Fornili M; Pruneri G; Van den Eynden G; Zoppoli G; Rothé F; Buisseret L; Garaud S; Willard-Gallo K; Brown D; Bareche Y; Rouas G; Galant C; Bertucci F; Loi S; Viale G; Di Leo A; Green AR; Ellis IO; Rakha EA; Larsimont D; Biganzoli E; Sotiriou C
    J Natl Cancer Inst; 2018 Jul; 110(7):768-776. PubMed ID: 29471435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
    Sestak I; Filipits M; Buus R; Rudas M; Balic M; Knauer M; Kronenwett R; Fitzal F; Cuzick J; Gnant M; Greil R; Dowsett M; Dubsky P
    Clin Cancer Res; 2020 Sep; 26(17):4682-4687. PubMed ID: 32561662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
    Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
    Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study.
    Tan RYC; Ong WS; Lee KH; Park S; Iqbal J; Park YH; Lee JE; Yu JH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Koh J; Han W; Im SA; Tan VKM; Phyu N; Wong FY; Tan PH; Yap YS
    J Natl Compr Canc Netw; 2024 May; 22(2D):. PubMed ID: 38744306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
    Chen Z; Yang J; Li S; Lv M; Shen Y; Wang B; Li P; Yi M; Zhao X; Zhang L; Wang L; Yang J
    PLoS One; 2017; 12(9):e0182397. PubMed ID: 28863134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
    Vaz-Luis I; Seah D; Olson EM; Wagle N; Metzger-Filho O; Sohl J; Litsas G; Burstein HJ; Krop IE; Winer EP; Lin NU
    Clin Breast Cancer; 2013 Aug; 13(4):254-63. PubMed ID: 23829891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.
    Lai HW; Tseng LM; Chang TW; Kuo YL; Hsieh CM; Chen ST; Kuo SJ; Su CC; Chen DR
    Breast; 2013 Oct; 22(5):968-73. PubMed ID: 23787124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.